MACOM Technology Solutions Holdings Inc. (NASDAQ: MTSI) shares are 7.97% up in the year-to-date (YTD) period and have moved -6.33% or -$1.94 lower in the latest trading session. However, stock’s trailing 12-month performance remains nearly +91.08% lower. Comparatively, the stock is -10.95% down YTD and 1.06% over the trailing 3-month period. If we look at the shorter duration, its week performance is 8.21% and 61.26% over the month.
On July 17, 2019, Piper Jaffray recommended the MTSI stock is a Overweight, while earlier, Needham had Reiterated the stock as a Buy on April 15, 2020. 12 analysts offering the recommendations for the stock have a consensus rating of 2.80 to suggest that the MTSI stock is a “Moderate Sell. 1 of the 12 analysts rate the stock as a “Sell”, while 1 has rated it as “Underweight”. 4 recommend buying, with 0 rating it as an Overweight.
The stock currently trades at $28.72 and analysts tracking its performance over the next 12 months have a consensus estimate price target of $27.40. The forecasts give the MACOM Technology Solutions Holdings Inc. stock a price target range of $40.00 on the higher side while at least one analyst think the stock could plunge to a low of $23.00. The two limits represent an upside potential of 28.2% or -24.87%.
Analysts estimate the earnings to increase 70.00% in the current quarter to $0.21, up from the -$0.42 reported in the same quarter a year ago. For the current year, earnings should grow to an average of $0.68, up 1.90% from -$0.29 reported last year. Analysts also offered guidance for the next financial quarter, with their average projected EPS at between $0.16 and $0.25. Wall Street estimates earnings per share to be at an average of $0.99 for the next year.
Insider Transactions Summary
According to SEC data, total insider shares purchases at the company stands at 31 over the last 12 months, while SEC filings reveal that there have been 17 insider sales over the same period. Insiders have purchases 517,077 shares while those sold by company executives and officers stand at 36,039. The last 3 months have seen insiders trade a total of 22,578 and 11,576 in purchases and sales respectively.
Kober John, a Senior VP and CFO at the company, sold 1,637 shares worth $47669.0 at $29.12 per share on Feb 18. The Senior VP and CFO had earlier sold another 1,662 MTSI shares valued at $49860.0 on Feb 19. The shares were sold at $30.00 per share. Roth Ambra R. (SVP, GC, HR & Secretary) sold 260 shares at $29.77 per share on Feb 11 for a total of $7740.0 while CARLSON DOUGLAS J, (SVP, Technology) sold 3,183 shares on Dec 27 for $86609.0 with each share fetching $27.21.
CRISPR Therapeutics AG (NASDAQ:CRSP), on the other hand, is trading around $48.46 with a market cap of $2.94B and analyst research firms have a negative stance on its shares. Analysts predict that the stock will reach $74.25 and spell out a more modest performance – a 34.73% return. Some analysts are even forecasting -$4.65 per share in earnings this year on a short term (1 year) basis.
Let us briefly look at the CRISPR Therapeutics AG (CRSP) financials, with a focus on its operating details as indicated in its earnings report for the last quarter.
Company balance sheet and cash flow
CRSP’s operating margin was positive on the trailing 12 months basis, remaining steady at 16.10%, while the operating expenses over the recent quarter were at -$73.59 million. This represented a 46970.06% of the company’s total revenues which amounted $157000.0. With this in place, we can see that the company’s diluted EPS declined -$1.15 on the year-over-year period, shrinking to -$0.93 as given in the last earnings report.
In terms of the balance sheet & cash flow as of (Jun 2020), the total assets figure advanced to $1.01 billion from $1.07 billion over the previous quarter. The cash flow from operating activities totaled -$52.17 million, significantly lower than the -$43.74 million reported in the year-ago quarter. The company’s free cash flow for the quarter was -$55.17 million.
Insiders have transacted a total of 12 times at CRISPR Therapeutics AG over the last 6 months, with insider purchases undertaken 5 times and accounting for 59,951 shares. Insider sales totaled 65,461 shares over the same period, with these deals completed in 7 transactions. Looking at these numbers, we realize that net purchases over that period are -2.0 shares. Insiders now hold a total of 12.78M shares after the latest sales, with 0.80% net shares purchased.
Insiders own 0.40% of the company shares, while shares held by institutions stand at 54.30% with a share float percentage of 48.07M. Investors are also buoyed by the number of investors in a company, with CRISPR Therapeutics AG having a total of 344 institutions that hold shares in the company. The top two institutional holders are Versant Venture Management, LLC with over 4.21 million shares worth more than $178.36 million. As of Mar 30, 2020, Versant Venture Management, LLC held 6.89% of shares outstanding.
The other major institutional holder is Nikko Asset Management Americas, Inc., with the investment firm holding over 3.77 million shares as of Mar 30, 2020. The firm’s total holdings are worth over $159.74 million and represent 6.17% of shares outstanding.